We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+32.66%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.98B
AUM Growth
+$533M
Cap. Flow
+$206M
Cap. Flow %
10.36%
Top 10 Hldgs %
47.31%
Holding
123
New
37
Increased
37
Reduced
31
Closed
16

Top Buys

Rank Stock Value
1
AVTR icon
Avantor
AVTR
+$27.7M
2
GSK icon
GSK
GSK
+$26.1M
3
ABVX
Abivax
ABVX
+$25.2M
4
EXAS
Exact Sciences
EXAS
+$19.4M
5
DHR icon
Danaher
DHR
+$19.1M

Top Sells

Rank Stock Value
1
ZIMV
ZimVie
ZIMV
+$39.4M
2
NTRA icon
Natera
NTRA
+$38.6M
3
QURE icon
uniQure
QURE
+$31.4M
4
RVTY icon
Revvity
RVTY
+$22.2M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.79%
2 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
26
Teva Pharmaceuticals
TEVA
$35.9B
$20.6M 1.04%
660,177
-703,476
-52% -$17.3M
UNH icon
27
UnitedHealth
UNH
$382B
$20.1M 1.01%
60,862
-1,958
-3% -$664K
TLT icon
28
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$42.1B
$20M 1.01%
+230,000
New +$20.6M
LQDA icon
29
Liquidia Corp
LQDA
$7.67B
$17.6M 0.89%
509,443
+23,422
+5% +$667K
ICLR icon
30
Icon
ICLR
$12.8B
$17.5M 0.88%
95,832
+40,807
+74% +$7.27M
HQY icon
31
HealthEquity
HQY
$7.91B
$17M 0.86%
185,739
+133,351
+255% +$12.8M
GKOS icon
32
Glaukos
GKOS
$9.02B
$16.7M 0.84%
+147,471
New +$14.1M
RVTY icon
33
Revvity
RVTY
$12.3B
$15.7M 0.79%
162,777
-231,534
-59% -$22.2M
NAMS icon
34
NewAmsterdam Pharma
NAMS
$3.47B
$14.8M 0.74%
420,827
-67,765
-14% -$2.47M
ESPR
35
DELISTED
Esperion Therapeutics
ESPR
$14.2M 0.72%
+3,851,133
New +$12.4M
BIIB icon
36
Biogen
BIIB
$29.9B
$13.7M 0.69%
77,944
+26,179
+51% +$4.28M
SEM
37
DELISTED
Select Medical
SEM
$13.5M 0.68%
+906,100
New +$12.8M
CNC icon
38
Centene
CNC
$31.3B
$13.3M 0.67%
324,092
+99,542
+44% +$3.73M
CGON icon
39
CG Oncology
CGON
$6.11B
$12.8M 0.65%
+308,466
New +$12.8M
BMY icon
40
Bristol-Myers Squibb
BMY
$127B
$12.7M 0.64%
+235,293
New +$11.3M
PALI icon
41
Palisade Bio
PALI
$339M
$12.7M 0.64%
+5,391,548
New +$10.4M
ARQT icon
42
Arcutis Biotherapeutics
ARQT
$3.42B
$12.6M 0.64%
434,634
+323,168
+290% +$8.27M
PHVS icon
43
Pharvaris
PHVS
$2.39B
$12.2M 0.61%
+439,177
New +$10.6M
XBI icon
44
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$12.1M 0.61%
+99,400
New +$11.4M
LLY icon
45
Eli Lilly
LLY
$1.07T
$11.4M 0.58%
+10,623
New +$10.2M
EHC icon
46
Encompass Health
EHC
$11.2B
$11.3M 0.57%
+106,926
New +$12.4M
CTMX icon
47
CytomX Therapeutics
CTMX
$705M
$10.7M 0.54%
+2,507,090
New +$9.52M
ELV icon
48
Elevance Health
ELV
$81.9B
$10.6M 0.53%
30,195
-14,785
-33% -$5M
MNKD icon
49
MannKind Corp
MNKD
$1.28B
$10.5M 0.53%
1,852,563
-190,164
-9% -$1.05M
XENE icon
50
Xenon Pharmaceuticals
XENE
$6.32B
$10.4M 0.52%
+231,380
New +$9.72M
1
2
3 4 5

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Eversept Partners held 123 positions worth $1.98B, up 37% from $1.45B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners deployed $206M of net new capital in Q4 2025, opening 37 new positions and adding to 37 existing holdings. Its largest new stake was Exact Sciences: 241,678 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 90% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Natera, an estimated $38.6M trimmed.

  • Eversept Partners's largest Q4 2025 buy was Exact Sciences: 241,678 shares worth $24.5M.
  • Eversept Partners added most to Avantor in Q4 2025, an estimated $27.7M increase.
  • Eversept Partners's biggest Q4 2025 reduction was Natera, cutting an estimated $38.6M.
  • Eversept Partners fully exited ZimVie in Q4 2025, selling an estimated $39.4M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.98B portfolio in Q4 2025.
  • Eversept Partners opened 37 new positions and closed 16 in Q4 2025.
  • Eversept Partners's portfolio value rose 37% quarter-over-quarter to $1.98B.

Based on Eversept Partners's 13F filing for Q4 2025, filed 17 Feb 2026.